Treatment of Venezuelan equine encephalitis virus infection with (-)-carbodine

Antiviral Research

Volumn 80, Issue 3, 2008, Pages 309-315

  Julander, Justin G ^a   Bowen, Richard A ^b   Rao, Jagadeeshwar R ^c   Day, Craig ^a   Shafer, Kristiina ^a   Smee, Donald F ^a   Morrey, John D ^a   Chu, Chung K ^c  

^a UTAH STATE UNIVERSITY   (United States)

^b Veterinary Dentistry and Oral Surgery   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

Author keywords

Antiviral; C3H HeN mouse; Carbodine; TC 83; Venezuelan equine encephalitis; Virus

Indexed keywords

CARBODINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DISEASE MODEL; DRUG EFFICACY; DRUG STRUCTURE; ENANTIOMER; ENCEPHALOMYELITIS; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS INHIBITION; VIRUS STRAIN;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; CYTIDINE; CYTIDINE TRIPHOSPHATE; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; ENCEPHALOMYELITIS, VENEZUELAN EQUINE; FEMALE; HUMANS; MICE; MICE, INBRED C3H; MICE, INBRED ICR; VERO CELLS;

EQUIDAE; MUS; VENEZUELAN EQUINE ENCEPHALITIS VIRUS;

EID: 56349132624     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.07.002     Document Type: Article

References (26)

1. Andrei G., and De Clercq E. Inhibitory effect of selected antiviral compounds on arenavirus replication in vitro. Antiviral Res. 14 (1990) 287-299
2. Berge T.O., Banks I.S., and Tigertt W.D. Attenuation of Venezuelan equine encephalomyelitis virus by in vitro cultivation in guinea-pig heart cells. Am. J. Hyg. 73 (1961) 209-218
3. Calisher C.H. Medically important arboviruses of the United States and Canada. Clin. Microbiol. Rev. 7 (1994) 89-116
4. De Clercq E., Bernaerts R., Shealy Y.F., and Montgomery J.A. Broad-spectrum antiviral activity of carbodine, the carbocyclic analogue of cytidine. Biochem. Pharmacol. 39 (1990) 319-325
5. Gumina G., Chong Y., Choo H., Song G.Y., and Chu C.K. l-Nucleosides: antiviral activity and molecular mechanism. Curr. Top. Med. Chem. 2 (2002) 1065-1086
6. Hart M.K., Pratt W., Panelo F., Tammariello R., and Dertzbaugh M. Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in BALB/c, but not C3H/HeN mice. Vaccine 15 (1997) 363-369
7. Hawley R.J., and Eitzen Jr. E.M. Biological weapons-a primer for microbiologists. Annu. Rev. Microbiol. 55 (2001) 235-253
8. Johnson B.J., Kinney R.M., Kost C.L., and Trent D.W. Molecular determinants of alphavirus neurovirulence: nucleotide and deduced protein sequence changes during attenuation of Venezuelan equine encephalitis virus. J. Gen. Virol. 67 Pt 9 (1986) 1951-1960
9. Julander J.G., Skirpstunas R., Siddharthan V., Shafer K., Hoopes J.D., Smee D.F., and Morrey J.D. C3H/HeN mouse model for the evaluation of antiviral agents for the treatment of Venezuelan equine encephalitis virus infection. Antiviral Res. 78 (2008) 230-241
10. Kinney R.M., Chang G.J., Tsuchiya K.R., Sneider J.M., Roehrig J.T., Woodward T.M., and Trent D.W. Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5′-noncoding region and the E2 envelope glycoprotein. J. Virol. 67 (1993) 1269-1277
11. Ludwig G.V., Turell M.J., Vogel P., Kondig J.P., Kell W.K., Smith J.F., and Pratt W.D. Comparative neurovirulence of attenuated and non-attenuated strains of Venezuelan equine encephalitis virus in mice. Am. J. Trop. Med. Hyg. 64 (2001) 49-55
12. Mathe C., and Gosselin G. l-Nucleoside enantiomers as antivirals drugs: a mini-review. Antiviral Res. 71 (2006) 276-281
13. Maury G. The enantioselectivity of enzymes involved in current antiviral therapy using nucleoside analogues: a new strategy?. Antivir. Chem. Chemother. 11 (2000) 165-189
14. Neyts J., Meerbach A., McKenna P., and De Clercq E. Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral Res. 30 (1996) 125-132
15. Politi P.M., Xie F., Dahut W., Ford Jr. H., Kelley J.A., Bastian A., Setser A., Allegra C.J., Chen A.P., Hamilton J.M., et al. Phase I clinical trial of continuous infusion cyclopentenyl cytosine. Cancer Chemother. Pharmacol. 36 (1995) 513-523
16. Rajappan V., Schneller S.W., Williams S.L., and Kern E.R. The enantiomers of carbocyclic 5′-norguanosine: activity towards Epstein-Barr virus. Bioorg. Med. Chem. 10 (2002) 883-886
17. Reed L.J., and Muench C.H. A simple method of estimating fifty percent endpoint. Am. J. Hyg. 27 (1938) 493-497
18. Schoneboom B.A., Catlin K.M., Marty A.M., and Grieder F.B. Inflammation is a component of neurodegeneration in response to Venezuelan equine encephalitis virus infection in mice. J. Neuroimmunol. 109 (2000) 132-146
19. Shannon W.M., Arnett G., Westbrook L., Shealy Y.F., O'Dell C.A., and Brockman R.W. Evaluation of carbodine, the carbocyclic analog of cytidine, and related carbocyclic analogs of pyrimidine nucleosides for antiviral activity against human influenza Type A viruses. Antimicrob. Agents Chemother. 20 (1981) 769-776
20. Sidwell R.W., and Huffman J.H. Use of disposable micro tissue culture plates for antiviral and interferon induction studies. Appl. Microbiol. 22 (1971) 797-801
21. Sidwell R.W., and Smee D.F. Viruses of the Bunya- and Togaviridae families: potential as bioterrorism agents and means of control. Antiviral Res. 57 (2003) 101-111
22. Spotts D.R., Reich R.M., Kalkhan M.A., Kinney R.M., and Roehrig J.T. Resistance to alpha/beta interferons correlates with the epizootic and virulence potential of Venezuelan equine encephalitis viruses and is determined by the 5′ noncoding region and glycoproteins. J. Virol. 72 (1998) 10286-10291
23. Weaver S.C. Host range, amplification and arboviral disease emergence. Arch Virol. Suppl. (2005) 33-44
24. Weaver S.C., Ferro C., Barrera R., Boshell J., and Navarro J.C. Venezuelan equine encephalitis. Annu. Rev. Entomol. 49 (2004) 141-174
25. Weaver S.C., Salas R., Rico-Hesse R., Ludwig G.V., Oberste M.S., Boshell J., and Tesh R.B. Re-emergence of epidemic Venezuelan equine encephalomyelitis in South America. VEE Study Group. Lancet 348 (1996) 436-440
26. White L.J., Wang J.G., Davis N.L., and Johnston R.E. Role of alpha/beta interferon in Venezuelan equine encephalitis virus pathogenesis: effect of an attenuating mutation in the 5′ untranslated region. J. Virol. 75 (2001) 3706-3718